Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies.
To determine the predictive value of early Phase trials (I-II) for the ocular hypotensive efficacy observed in Phases III and IV. A review of published literature. This study evaluated 12 medicines in 65 articles in the literature with at least two phases available. For medicines with Phase I results available (n=3), the average reduction in intraocular pressure (IOP) from untreated baseline was 16%, 26% for Phase II, 26% for Phase III, and 24% for Phase IV. For medicines with Phase II results available (n=6), the average reduction in IOP was 23%, 24% for Phase III, and 23% for Phase IV. For medicines with Phase III results available (n=11), the average reduction in IOP was 25% and 24% for Phase IV. This study indicates that early phase trials usually approximated the results of later regulatory studies and post-commercialization trials.